Sign in
WithdrawnPhase 4

Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT

Key facts

Who runs it
Tuen Mun Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Phase
Phase 4
Started
29 Sept 2026
Ended
29 Sept 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • recombinant subunit herpes zoster vaccine
Record updated
1 October 2026
Why it stopped
lack of funding

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Patients with a diagnosis of rheumatic or immune-mediated diseases eg. SLE, RA, PSA, SpA, inflammatory myopathies, ANCA-related and large vessel vasculitides
  • Age ≥18 years
  • Stable or reducing doses of any the following immunosuppressive regimens within 4 weeks of study entry:; Prednisolone ≥20mg/kg/day ± mycophenolate mofetil, azathioprine or the calcineurin inhibitors; Cyclophosphamide (intravenous pulses or daily oral); B-cell depleting biological agents and their biosimilars eg. belimumab, anti-CD20 agents (next scheduled dose should be arranged to at least 12 weeks after study entry for rituximab or obinutuzumab); Anti-TNFα biological agents and their biosimilars eg. infliximab, etanercept, adalimumab, golimumab, certolizumab; Anti-interleukin-6 biological agents eg. tocilizumab, sarilumab; Other biological agents eg. abatacept, ustekinumab, secukinumab, ixekizumab; The JAK inhibitors eg. tofacitinib, baricitinib, upadacitinib
  • Female patients with reproductive potential are allowed to participate in this study provided that they are willing to practice contraception for until at least 12 months after vaccination
  • Willing to comply with all study procedures

Who cannot take part

  • Active infection, including upper respiratory tract infection
  • Active HZ infection
  • Active untreated tuberculosis
  • HIV infection
  • History of HZ or varicella vaccination in the past
  • History of allergy to any vaccines
  • Patients who are pregnant or plan to become pregnancy within one year of study entry
  • Lactating women
  • Patients who cannot give a written consent (mentally incapable or illiterate)

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

A double-blind randomized controlled trial on the safety and immunogenicity of the recombinant subunit herpes zoster vaccine, Shingrix, in patients with rheumatic diseases undergoing immunosuppressive or biologic/targeted DMARD therapies

The 2 groups in the trial

  • vaccineExisting treatment, for comparison

    Shingrix vaccine

    Treatment: recombinant subunit herpes zoster vaccine

  • placeboPlacebo, for comparison

    normal saline injection (0.5mL)

    Treatment: recombinant subunit herpes zoster vaccine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Immunogenicity of a Recombinant Subunit Herpes Zoster Vaccine in Patients With Rheumatic Diseases Undergoing Immunosuppressive or Biologic/Targeted DMARD Therapies: a Double-blind Randomized Placebo-controlled Trial
Record updated
1 October 2026